Carbapenem-based Antibiotics is anticipated to have CAGR of ~7.2% over 2019-2028. Carbapenems are a class of highly effective antibiotic agents mainly used for the treatment of severe or high-risk bacterial infections. The rise in the incidences of the bacterial infections would help the industry to grow in the forecast period. Furthermore, there have been incidences wherein the Pneumonia has been acquired in the hospital settings if stayed for longer time, and can be managed only with the help of Carbapenem-based antibiotics. This advantage over the other drugs would help the market grow significantly. The growth in the number of surgeries and hence the infections acquired due to the exposure directly to the environment leading to cause an infectious disease. This would boost the industry in the coming years.

Top Driver: Surge In The Surgery- Associated Bacterial Infection To Propel The Industry

Carbapenem-based Antibiotics is projected to grow with the increase in the number of surgery-associated bacterial infections, attributed to help the industry grow significantly in the forecast period. According to the recent article given by the Center for Disease Control and Prevention, approximately 27 million surgical procedures are performed in the United States each year, with up to 5% resulting in surgical site infections (SSI). The increase in the awareness regarding the surgical infections is anticipated to help the industry grow at a lucrative growth in the coming years. Furthermore, the rise in the investments over the Carbapenem-based drugs in order to develop it in to help in management of the bacterial infections would help the industry to boost in the near future.

Ertapenem to Make Crucial Contribution to Growth of Global Carbapenem-based Antibiotics Market

Among product segments of the global Carbapenem-based Antibiotics market, Ertapenem is anticipated to gain highest revenue shares in the forecast period. The advantages over the other drugs are helping the Ertapenem drug to gain maximum popularity and are expected to contribute to a lucrative growth in the industry in the coming years. The growth in the number of prescriptions for Ertapenem is anticipated to boost the industry in the near future. Furthermore, Meropenem is experiencing the highest CAGR, due to the increase in the awareness program for the use of Meropenem as an alternative of the Ertapenem. The growth in the efficacy results will help the industry gain growth in the coming few years.

   Surge in the patient population to Benefit North American Market

North America is estimated to experience highest revenue growth than any other country and is anticipated to boost further in the coming years. The steep rise in the patient population would help the industry propel. According to the recent article from AHRQ, 10 million patients undergo surgical procedures as inpatients each year, accounting for over one-fourth of all hospital stays.  Furthermore, the Asia Pacific region is anticipated to experience lucrative growth due to the surge in the healthcare expenditure and the growth in the awareness programs for improving the quality of life in the near future.

Due to outbreak of COVID-19 the Carbapenem-based Antibiotics is anticipated to grow due to the advantage in preventing the bacterial infections. However, the government has invested more upon the development of vaccines which would help the pharmaceutical industries to gain a lucrative growth in the current scenario.

Players to Focus on Carbapenem-based Antibiotics

The global Carbapenem-based Antibiotics market leaders include ACS Dobfar S.p.A., Apotex, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Daewoong Pharmaceutical Co., Ltd., Fedora Pharmaceuticals, Inc., Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.), Iterum Therapeutics plc, Jeil Pharmaceutical Co., Ltd., and Johnson & Johnson Pharmaceuticals.

Amneal Pharmaceuticals LLC: In May 2018, Amneal Pharmaceuticals LLC and Impax Laboratories, Inc., announced that they have completed their business combination to form Amneal Pharmaceuticals, Inc. As a diversified company with a robust generics business, Amneal is now the 5th largest generics business in the United States, with a growing, high-margin specialty franchise.

Daewoong Pharmaceutical: In April 2017, Daewoong Pharmaceutical had launched its generic antibiotic “Meropenem” in the United States. Meropenem is Daewoong’s first product exported to the American market and the first Korean generic drug sold the world’s largest medicine market. It won the approval of the U.S. Food and Drug Administration in December 2015 and will be sold there in earnest

Johnson & Johnson Pharmaceuticals: In December 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson  announced the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees, from XBiotech Inc., for $750 million.

Scope of the Report

By Product

• Meropenem
• Ertapenem
• Imipenem
• Doripenem
• Others
  

By Indications

• Intra-abdominal Infections
• Urinary Tract Infections
• Respiratory Tract Infection
• Bacterial Meningitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.